ACE and COVID-19: In this regard, the self-discontinuation of ACE-I/ARB therapy in fear of severe COVID-19 might be underreported in registries.12 Moreover, these aforementioned studies did not describe the characteristics of ACE-I/ARB therapy, including dosing and complications such as hyperkalemia.